SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is facing heavy selling pressure after raising its full-year capital expenditure guidance to support AI infrastructure, despite delivering strong revenue growth and earnings beats. Investors remain deeply divided, with many expressing frustration over the persistent spending cycle while others view the dip as a tactical buying opportunity in a growth-focused leader.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is trending as a high-volatility, low-float momentum play that community members are aggressively trading as a potential short squeeze candidate. Traders are actively debating whether this is a sustainable rally or a pump-and-dump, focusing on elevated cost-to-borrow rates and the stock's tendency for rapid, multi-day spikes reminiscent of past microcap runners.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing massive momentum and extreme retail interest as it tests the hundred-dollar level, fueled by rumors of an Apple partnership, ongoing foundry execution, and high-profile support from President Trump. The community remains deeply divided, with bulls pointing to fundamental turnaround progress and institutional backing, while bears caution against a potential 'pump and dump' setup and excessive valuations that defy historical norms.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors react to reports of a custom AI chip partnership with Marvell, while community sentiment remains focused on the company's aggressive infrastructure spending and Cloud growth ahead of earnings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened anticipation ahead of upcoming earnings, with investors closely watching for updates on the Phase 3 obesity program and potential pipeline expansions. The community remains focused on the long-term potential of its dual agonist VK2735, debating whether standalone development or a major partnership/buyout represents the most viable path to unlocking value.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

Jaguar Health is trending as investors react to a looming 1-for-35 reverse stock split and ongoing delisting concerns, fueling intense community debate between vocal bagholders and skeptics. The conversation is dominated by discussions regarding the company's long history of repeated splits, heavy dilution, and the critical need for clinical data to validate its rare-disease pipeline.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a surge in investor attention driven by sector-wide momentum as competitors like Bloom Energy announce significant data center partnerships, highlighting a growing market demand for reliable, on-site power solutions. The community is actively discussing the potential for a long-awaited contract or deal that could serve as a catalyst for a re-rating, though sentiment remains tempered by ongoing concerns regarding share dilution and management's execution track record.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is drawing significant investor interest as the market closely monitors its massive multi-billion dollar AI infrastructure expansion in India, with community discussion intensely focused on whether these large-scale contract headlines will finally translate into sustained revenue and a potential short squeeze. Traders are actively debating the company's valuation, insider ownership stability, and the high-beta risk profile of a low-float stock that historically experiences violent price swings on AI narrative momentum.

Goldfinch is a DeFi protocol that brings crypto loans to the real world.

Goldfinch

Goldfinch is seeing renewed market attention as traders highlight its role in the Real World Asset sector and its low circulating supply, with many discussing potential for significant gains alongside other major RWA projects. While some community members remain skeptical of its price action and label it volatile, others are aggressively accumulating during pullbacks, citing long-term utility and institutional connections as key drivers for future upside.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors aggressively position themselves ahead of its highly anticipated earnings report, with the community closely watching whether Google Cloud's recent growth and AI integration can justify the company's massive capital expenditure. While the broader market remains cautious due to macroeconomic uncertainty, sentiment around the stock is heavily bullish, fueled by institutional accumulation and the expectation that Alphabet will solidify its competitive standing in the ongoing AI infrastructure arms race.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has i...

Fulcrum Therapeutics (NASDAQ:FULC) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) posted its earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06...

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell...

Fulcrum Therapeutics Q1 Earnings Call Highlights

Fulcrum Therapeutics (NASDAQ:FULC) highlighted new clinical and corporate progress during its first-quarter 2026 financial results and business update call, with management emphasizing positive Phase...

Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9% - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.9% - Here's What Happened...

Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Grows By 41.1%

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling...

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Fulcrum Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday...

Aberdeen Group plc Has $14.18 Million Stock Holdings in Fulcrum Therapeutics, Inc. $FULC

Aberdeen Group plc raised its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 809.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and sev...

$FULC Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.25 up 10.71% YoY
• Fulcrum Therapeutics expects existing cash, cash equivalents, and marketable securities of $333.3 million as of March 31, 2026, to fund operating expenses and capital expenditures into 2029. The company also plans to provide next trial design details in Q2 2026.

Stocktwits

Fulcrum Therapeutics Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.25 up 10.71% YoY
• Fulcrum Therapeutics expects existing cash, cash equivalents, and marketable securities of $333.3 million as of March 31, 2026, to fund operating expenses and capital expenditures into 2029. The company also plans to provide next trial design details in Q2 2026.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

$GOOGL

$MSFT

$AMZN

$META

Which Mag 7 name makes the biggest move after earnings today?

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest FULC News

FULCFulcrum Therapeutics Inc